EcoDrugPlus

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSSCAG00000011733
Gene Symbol: GRIN2A
3 Cross references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSSCAG00000006355
Gene Symbol: GRIN2B
3 Cross references
330 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSSCAG00000005801
Gene Symbol: GRIN3A
1 Cross references
245 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSSCAG00000005915
Gene Symbol: GRIN3B
1 Cross references
286 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSSCAG00000013503
Gene Symbol: GRIK1
3 Cross references
302 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSSCAG00000001013
Gene Symbol: GRIK2
3 Cross references
332 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSSCAG00000015246
Gene Symbol: GRIK3
1 Cross references
256 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSSCAG00000008163
Gene Symbol: GRIK4
1 Cross references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSSCAG00000017148
Gene Symbol: GRM2
3 Cross references
276 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSSCAG00000008905
Gene Symbol: GRM3
3 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSSCAG00000015992
Gene Symbol: GRM4
1 Cross references
271 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSSCAG00000003123
Gene Symbol: GRM5
3 Cross references
283 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).